Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Cipla
Harvard Business School
Merck
Accenture
Deloitte
Daiichi Sankyo
Express Scripts
Colorcon

Generated: August 17, 2018

DrugPatentWatch Database Preview

FINACEA Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Finacea patents expire, and when can generic versions of Finacea launch?

Finacea is a drug marketed by Bayer Hlthcare and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and ninety-five patent family members in thirty-one countries.

The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the azelaic acid profile page.

Drug patent expirations by year for FINACEA
Generic Entry Opportunity Date for FINACEA
Generic Entry Dates for FINACEA *:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
AEROSOL, FOAM;TOPICAL
Generic Entry Dates for FINACEA *:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
GEL;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for FINACEA
Synonyms for FINACEA
0C50D8EC-0DB0-4F24-8EFC-2919E1F0D9BF
1,7-Dicarboxyheptane
1,7-Heptanedicarboxylate
1,7-Heptanedicarboxylic acid
1,9-Nonanedioate
1,9-Nonanedioic acid
123-99-9
123-99-9 (Parent)
17265-13-3 (di-hydrochloride salt)
17356-30-8 (mono-hydrochloride salt)
19619-43-3 (unspecified potassium salt)
1tuf
21175-EP2269988A2
21175-EP2270008A1
21175-EP2275413A1
21175-EP2287156A1
21175-EP2292617A1
21175-EP2301940A1
21175-EP2314295A1
21175-EP2374895A1
21175-EP2380874A2
26776-28-3
27825-99-6
27825-99-6 (unspecified hydrochloride salt)
32733-99-6
38900-29-7 (di-lithium salt)
4-02-00-02055 (Beilstein Handbook Reference)
52457-54-2 (di-potassium salt)
A-9800
A0561
AB00052140_12
AC1L1DAO
AC1Q75FC
acide azelaique
Acide azelaique [French]
Acido azelaico
Acido azelaico [Spanish]
Acidum acelaicum
acidum azelaicum
Acidum azelaicum [Latin]
ACMC-1BTAP
AGN-191861
AI3-06299
AK174117
AKOS000120052
AN-22935
Anchoate
Anchoic acid
ANW-18182
ARONIS24596
AZ1
Azalaic Acid
Azelaic
azelaic acid
Azelaic acid (USAN/INN)
Azelaic acid [USAN:INN]
Azelaic acid 99%
azelaic acid dipotassium salt
Azelaic acid polyanhydride
AZELAIC ACID, 95%
Azelaic acid, 98%
Azelaic acid, 98% 25g
Azelaic acid, analytical standard
Azelaic acid, technical grade
Azelaic acid, technical grade, 80%
Azelaic acid, technical, ~85% (GC)
Azelaic acid, Vetec(TM) reagent grade
Azelaic acid,technical grade
Azelaic polyanhydride
azelaicacid
Azelaicacidtech
Azelainic acid
Azelainsaeure
Azelainsaure
azelate
Azelex
Azelex (TN)
Azleaic Acid
BDJRBEYXGGNYIS-UHFFFAOYSA-N
BIDD:GT0315
BRN 1101094
BSPBio_001756
C08261
CAS-123-99-9
CCG-40081
CHEBI:48131
CHEMBL1238
CTK0H8917
D03034
D0E4WR
DB00548
Dicarboxylic acid C9
Dicarboxylic acid C9; Nonanedioic acid; AZA
DivK1c_000532
DSSTox_CID_1640
DSSTox_GSID_21640
DSSTox_RID_76254
DTXSID8021640
EINECS 204-669-1
Emerox 1110
Emerox 1144
Emery's L-110
Epitope ID:187039
EU-0100051
F2VW3D43YT
F8889-5093
Finacea (TN)
Finevin
Finevin (TN)
FT-0626920
GTPL7484
heptane-1,7-dicarboxylic acid
Heptanedicarboxylic acid
HMS1921O11
HMS2092E22
HMS2234D10
HMS3260K03
HMS3372J07
HMS501K14
HSDB 7659
HY-B0704
I04-0585
IDI1_000532
InChI=1/C9H16O4/c10-8(11)6-4-2-1-3-5-7-9(12)13/h1-7H2,(H,10,11)(H,12,13
KB-74817
KBio1_000532
KBio2_000437
KBio2_003005
KBio2_005573
KBio3_001256
KBioGR_000662
KBioSS_000437
KS-00000WLV
KS-000046KE
KS-5293
KSC178S1P
Lepargylate
Lepargylic acid
LMFA01170054
Lopac-246379
Lopac0_000051
LP00051
LP083134
LS-22779
LS41867
M112324
MCULE-4093240509
MFCD00004432
MLS-0066619
MLS-0066619.P021
MLS000069659
MLS001148615
MolPort-001-779-873
n-Nonanedioate
n-Nonanedioic acid
NCGC00014993-01
NCGC00014993-02
NCGC00014993-03
NCGC00014993-04
NCGC00014993-05
NCGC00014993-06
NCGC00014993-07
NCGC00014993-08
NCGC00014993-09
NCGC00014993-10
NCGC00014993-12
NCGC00093565-01
NCGC00093565-02
NCGC00093565-03
NCGC00093565-04
NCGC00093565-05
NCGC00093565-06
NCGC00093565-07
NCGC00256508-01
NCGC00259538-01
NCGC00260736-01
NE10317
NINDS_000532
Nonandisaeure
Nonandisaure
NONANEDIOIC ACID
Nonanedioic acid Azelaic acid
Nonanedioic acid homopolymer
Nonanedioic acid, homopolymer
Nonanedioic acid, sodium salt
NSC 19493
NSC-19493
NSC-757406
NSC19493
NSC757406
Opera_ID_740
Pharmakon1600-01500648
Poly(azelaic anhydride)
Polyazelaic anhydride
Polyazelaic Polyanhydride
RP17465
RTR-003741
s4550
SBB060279
SBI-0050040.P003
SC-16119
SCHEMBL3887
SDCCGMLS-0066619.P001
SH-441
Skinorem
Skinoren
Skinoren (TN)
SMR000059164
SPBio_001089
Spectrum_000057
SPECTRUM1500648
Spectrum2_000995
Spectrum3_000278
Spectrum4_000401
Spectrum5_001304
SR-01000075671
SR-01000075671-1
ST45053319
STL059432
Tox21_110063
Tox21_110063_1
Tox21_201989
Tox21_303011
Tox21_500051
TR-003741
TRA0060478
UNII-F2VW3D43YT
Z57127532
ZINC1531036
ZK 62498
ZK-62498

US Patents and Regulatory Information for FINACEA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare FINACEA azelaic acid AEROSOL, FOAM;TOPICAL 207071-001 Jul 29, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Hlthcare FINACEA azelaic acid AEROSOL, FOAM;TOPICAL 207071-001 Jul 29, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Bayer Hlthcare FINACEA azelaic acid AEROSOL, FOAM;TOPICAL 207071-001 Jul 29, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Bayer Hlthcare FINACEA azelaic acid AEROSOL, FOAM;TOPICAL 207071-001 Jul 29, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Hlthcare FINACEA azelaic acid AEROSOL, FOAM;TOPICAL 207071-001 Jul 29, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Hlthcare FINACEA azelaic acid AEROSOL, FOAM;TOPICAL 207071-001 Jul 29, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for FINACEA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,622,947 Foamable composition combining a polar solvent and a hydrophobic carrier ➤ Try a Free Trial
7,645,803 Saccharide foamable compositions ➤ Try a Free Trial
9,320,705 Sensation modifying topical composition foam ➤ Try a Free Trial
8,795,693 Compositions with modulating agents ➤ Try a Free Trial
9,636,405 Foamable vehicle and pharmaceutical compositions thereof ➤ Try a Free Trial
8,518,378 Oleaginous pharmaceutical and cosmetic foam ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

International Patents for FINACEA

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Fuji
Chinese Patent Office
Farmers Insurance
Harvard Business School
Healthtrust
Cipla
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.